Literature DB >> 18245080

Mapping and characterization of the binding site for specific oxidized phospholipids and oxidized low density lipoprotein of scavenger receptor CD36.

Niladri S Kar1, Mohammad Z Ashraf, Manojkumar Valiyaveettil, Eugene A Podrez.   

Abstract

Recent studies have identified a novel family of oxidized phosphatidylcholines (oxPC(CD36)) that serve as highly specific ligands for scavenger receptor CD36. oxPC(CD36) accumulate in vivo and mediate macrophage foam cell formation as well as promote platelet hyper-reactivity in hyperlipidemia via CD36. The structural basis of oxPC(CD36) binding to CD36 has not been elucidated. We used liquid-phase binding to glutathione S-transferase fusion proteins containing various regions of CD36 to initially identify the region spanning CD36 amino acids 157-171 to contain a major binding site for oxPC(CD36). A bell-shaped pH profile and salt concentration dependence suggest an electrostatic mechanism of the binding. Two conserved, positively charged amino acids in the region 157-171 (lysines at positions 164 and 166) were identified as critical for oxPC(CD36) and oxidized low density lipoprotein (oxLDL) binding to CD36. Lysine neutralization with chemical modifier or site-directed mutagenesis of lysine 164/166 to alanine or glutamate, but not to arginine, abolished binding. Cells expressing full-length CD36 with mutated lysines (164 and 166) failed to recognize oxPC(CD36) and oxLDL. Synthetic peptides mimicking the CD36 binding site, but not mutated or scrambled peptides, effectively prevented: (i) oxLDL binding to CD36, (ii) macrophage foam cell formation induced by oxLDL, and (iii) platelet activation by oxPC(CD36). These data indicate that CD36 (160-168) represents the core of the oxPC(CD36) binding site with lysines 164/166 being indispensable for the binding.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18245080      PMCID: PMC2417175          DOI: 10.1074/jbc.M709195200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

Review 1.  CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism.

Authors:  M Febbraio; D P Hajjar; R L Silverstein
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

2.  Defect in human myocardial long-chain fatty acid uptake is caused by FAT/CD36 mutations.

Authors:  T Tanaka; T Nakata; T Oka; T Ogawa; F Okamoto; Y Kusaka; K Sohmiya; K Shimamoto; K Itakura
Journal:  J Lipid Res       Date:  2001-05       Impact factor: 5.922

3.  Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species.

Authors:  E A Podrez; M Febbraio; N Sheibani; D Schmitt; R L Silverstein; D P Hajjar; P A Cohen; W A Frazier; H F Hoff; S L Hazen
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

4.  The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein.

Authors:  A Boullier; K L Gillotte; S Hörkkö; S R Green; P Friedman; E A Dennis; J L Witztum; D Steinberg; O Quehenberger
Journal:  J Biol Chem       Date:  2000-03-31       Impact factor: 5.157

5.  CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart.

Authors:  V Bodart; M Febbraio; A Demers; N McNicoll; P Pohankova; A Perreault; T Sejlitz; E Escher; R L Silverstein; D Lamontagne; H Ong
Journal:  Circ Res       Date:  2002-05-03       Impact factor: 17.367

6.  Requirements of basic amino acid residues within the lectin-like domain of LOX-1 for the binding of oxidized low-density lipoprotein.

Authors:  M Chen; K Inoue; S Narumiya; T Masaki; T Sawamura
Journal:  FEBS Lett       Date:  2001-06-22       Impact factor: 4.124

7.  Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36.

Authors:  Eugene A Podrez; Eugenia Poliakov; Zhongzhou Shen; Renliang Zhang; Yijun Deng; Mingjiang Sun; Paula J Finton; Lian Shan; Bogdan Gugiu; Paul L Fox; Henry F Hoff; Robert G Salomon; Stanley L Hazen
Journal:  J Biol Chem       Date:  2002-07-08       Impact factor: 5.157

8.  A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions.

Authors:  Eugene A Podrez; Eugenia Poliakov; Zhongzhou Shen; Renliang Zhang; Yijun Deng; Mingjiang Sun; Paula J Finton; Lian Shan; Maria Febbraio; David P Hajjar; Roy L Silverstein; Henry F Hoff; Robert G Salomon; Stanley L Hazen
Journal:  J Biol Chem       Date:  2002-07-26       Impact factor: 5.157

9.  Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study.

Authors:  Annie Demers; Normand McNicoll; Maria Febbraio; Marc Servant; Sylvie Marleau; Roy Silverstein; Huy Ong
Journal:  Biochem J       Date:  2004-09-01       Impact factor: 3.857

10.  Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype.

Authors:  Eugene A Podrez; Tatiana V Byzova; Maria Febbraio; Robert G Salomon; Yi Ma; Manojkumar Valiyaveettil; Eugenia Poliakov; Mingjiang Sun; Paula J Finton; Brian R Curtis; Juhua Chen; Renliang Zhang; Roy L Silverstein; Stanley L Hazen
Journal:  Nat Med       Date:  2007-08-26       Impact factor: 53.440

View more
  39 in total

1.  TLR2 Plays a Key Role in Platelet Hyperreactivity and Accelerated Thrombosis Associated With Hyperlipidemia.

Authors:  Sudipta Biswas; Alejandro Zimman; Detao Gao; Tatiana V Byzova; Eugene A Podrez
Journal:  Circ Res       Date:  2017-08-03       Impact factor: 17.367

2.  Reductive metabolism increases the proinflammatory activity of aldehyde phospholipids.

Authors:  Elena Vladykovskaya; Evgeny Ozhegov; J David Hoetker; Zhengzhi Xie; Yonis Ahmed; Jill Suttles; Sanjay Srivastava; Aruni Bhatnagar; Oleg A Barski
Journal:  J Lipid Res       Date:  2011-09-27       Impact factor: 5.922

Review 3.  Regulation of platelet function by class B scavenger receptors in hyperlipidemia.

Authors:  Alejandro Zimman; Eugene A Podrez
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

4.  OxLDL or TLR2-induced cytokine response is enhanced by oxLDL-independent novel domain on mouse CD36.

Authors:  Chenghui Xie; Hangpong Ng; Shanmugam Nagarajan
Journal:  Immunol Lett       Date:  2011-01-31       Impact factor: 3.685

Review 5.  Scavenger receptors in homeostasis and immunity.

Authors:  Johnathan Canton; Dante Neculai; Sergio Grinstein
Journal:  Nat Rev Immunol       Date:  2013-08-09       Impact factor: 53.106

6.  Structure of LIMP-2 provides functional insights with implications for SR-BI and CD36.

Authors:  Dante Neculai; Michael Schwake; Mani Ravichandran; Friederike Zunke; Richard F Collins; Judith Peters; Mirela Neculai; Jonathan Plumb; Peter Loppnau; Juan Carlos Pizarro; Alma Seitova; William S Trimble; Paul Saftig; Sergio Grinstein; Sirano Dhe-Paganon
Journal:  Nature       Date:  2013-10-27       Impact factor: 49.962

Review 7.  Structure-function of CD36 and importance of fatty acid signal transduction in fat metabolism.

Authors:  Marta Yanina Pepino; Ondrej Kuda; Dmitri Samovski; Nada A Abumrad
Journal:  Annu Rev Nutr       Date:  2014-05-16       Impact factor: 11.848

8.  Structural basis for the recognition of oxidized phospholipids in oxidized low density lipoproteins by class B scavenger receptors CD36 and SR-BI.

Authors:  Detao Gao; Mohammad Z Ashraf; Niladri S Kar; De Lin; Lawrence M Sayre; Eugene A Podrez
Journal:  J Biol Chem       Date:  2009-12-08       Impact factor: 5.157

9.  Macrophage heterogeneity and cholesterol homeostasis: classically-activated macrophages are associated with reduced cholesterol accumulation following treatment with oxidized LDL.

Authors:  Eugene M Chu; Daven C Tai; Jennifer L Beer; John S Hill
Journal:  Biochim Biophys Acta       Date:  2012-11-08

Review 10.  Detection and treatment of atherosclerosis using nanoparticles.

Authors:  Jia Zhang; Yujiao Zu; Chathurika S Dhanasekara; Jun Li; Dayong Wu; Zhaoyang Fan; Shu Wang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.